Department of Hematology
Gert Ossenkoppele has not added Biography.
If you are Gert Ossenkoppele and would like to personalize this page please email our Author Liaison for assistance.
Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma.
Blood Jun, 2002 | Pubmed ID: 12036886
Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia.
Haematologica Feb, 2003 | Pubmed ID: 12604403
Serum-free generation of antigen presenting cells from acute myeloid leukaemic blasts for active specific immunisation.
Cancer immunology, immunotherapy : CII Jul, 2003 | Pubmed ID: 12690520
ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects--a review.
The Journal of pathology May, 2003 | Pubmed ID: 12692835
Differences between the CD34+ and CD34- blast compartments in apoptosis resistance in acute myeloid leukemia.
Haematologica May, 2003 | Pubmed ID: 12745269
Novel multiparameter flow cytometry assay using Syto16 for the simultaneous detection of early apoptosis and apoptosis-corrected P-glycoprotein function in clinical samples.
Cytometry. Part B, Clinical cytometry Sep, 2003 | Pubmed ID: 12949955
Assessment of the normal or leukemic nature of CD34+ cells in acute myeloid leukemia with low percentages of CD34 cells.
Haematologica Sep, 2003 | Pubmed ID: 12969806
Emerging antibody-targeted therapy in leukemia and lymphoma: current concepts and clinical implications.
Anti-cancer drugs Mar, 2004 | Pubmed ID: 15014351
The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients.
Blood Apr, 2004 | Pubmed ID: 15070662
Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome.
Cancer research Aug, 2004 | Pubmed ID: 15313888
Antibody-targeted therapy: a paradigm of innovative treatment strategies in indolent and aggressive B-cell non-Hodgkin lymphoma.
Current opinion in hematology Nov, 2004 | Pubmed ID: 15548997
Purging of peripheral blood stem cell transplants in AML: a predictive model based on minimal residual disease burden.
Experimental hematology Jan, 2005 | Pubmed ID: 15661405
Minimal residual disease in acute myeloid leukemia is predicted by an apoptosis-resistant protein profile at diagnosis.
Clinical cancer research : an official journal of the American Association for Cancer Research Apr, 2005 | Pubmed ID: 15814631
Quantification of T-cell-mediated apoptosis in heterogeneous leukemia populations using four-color multiparameter flow cytometry.
Cytometry. Part A : the journal of the International Society for Analytical Cytology Jul, 2005 | Pubmed ID: 15895438
Immunologic purging of autologous peripheral blood stem cell products based on CD34 and CD133 expression can be effectively and safely applied in half of the acute myeloid leukemia patients.
Clinical cancer research : an official journal of the American Association for Cancer Research Jul, 2005 | Pubmed ID: 16000576
Employing the immunological synapse in AML: development of leukemic dendritic cells for active specific immunization.
Immunobiology , 2005 | Pubmed ID: 16164032
High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival.
Clinical cancer research : an official journal of the American Association for Cancer Research Sep, 2005 | Pubmed ID: 16166428
Leukemia-derived dendritic cells: towards clinical vaccination protocols in acute myeloid leukemia.
Haematologica Mar, 2006 | Pubmed ID: 16531258
Principles of dendritic cell-based immunotherapy in myeloid leukemia.
Immunobiology , 2006 | Pubmed ID: 16920505
Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia.
Immunobiology , 2006 | Pubmed ID: 16920506
Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells.
Blood Mar, 2007 | Pubmed ID: 17068146
Leukemia-specific T-cell reactivity induced by leukemic dendritic cells is augmented by 4-1BB targeting.
Clinical cancer research : an official journal of the American Association for Cancer Research Jan, 2007 | Pubmed ID: 17170077
CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age.
Annals of hematology May, 2007 | Pubmed ID: 17340137
Activated intrinsic apoptosis pathway is a key related prognostic parameter in acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Apr, 2007 | Pubmed ID: 17401010
Small-molecule XIAP antagonist restores caspase-9 mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells.
Blood Jan, 2008 | Pubmed ID: 17916749
Chemotherapeutic treatment of bone marrow stromal cells strongly affects their protective effect on acute myeloid leukemia cell survival.
Leukemia & lymphoma Jan, 2008 | Pubmed ID: 17926185
Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry.
Blood Feb, 2008 | Pubmed ID: 17971483
Inhibition of the intrinsic apoptosis pathway downstream of caspase-9 activation causes chemotherapy resistance in diffuse large B-cell lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research Dec, 2007 | Pubmed ID: 18056177
Positive selection for CD90 as a purging option in acute myeloid leukemia stem cell transplants.
Cytometry. Part B, Clinical cytometry Jan, 2008 | Pubmed ID: 18061946
Concurrent methylation of promoters from tumor associated genes predicts outcome in acute myeloid leukemia.
Leukemia & lymphoma Jun, 2008 | Pubmed ID: 18569637
Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia.
Haematologica Jan, 2009 | Pubmed ID: 19042917
Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia.
Stem cells (Dayton, Ohio) Dec, 2008 | Pubmed ID: 19096043
Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome.
Haematologica Apr, 2009 | Pubmed ID: 19229054
Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML.
European journal of cancer (Oxford, England : 1990) Jun, 2009 | Pubmed ID: 19321337
Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes.
Haematologica Aug, 2009 | Pubmed ID: 19546437
A 51-year-old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment.
American journal of hematology Oct, 2009 | Pubmed ID: 19658186
Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.
Haematologica Mar, 2010 | Pubmed ID: 19903675
Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment.
Blood Mar, 2010 | Pubmed ID: 20038788
Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles.
The Journal of pathology Apr, 2010 | Pubmed ID: 20087881
Methylation patterns in CD34 positive chronic myeloid leukemia blast crisis cells.
Haematologica Jun, 2010 | Pubmed ID: 20421276
New approaches for the detection of minimal residual disease in acute myeloid leukemia.
Current hematologic malignancy reports May, 2007 | Pubmed ID: 20425359
Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia.
Immunotherapy Jan, 2010 | Pubmed ID: 20635890
Impaired antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia.
Immunotherapy Jan, 2010 | Pubmed ID: 20635891
Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes.
Cancer immunology, immunotherapy : CII Dec, 2010 | Pubmed ID: 20820776
Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation.
Cancer immunology, immunotherapy : CII Jan, 2011 | Pubmed ID: 20859626
Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells.
Cancer research Apr, 2011 | Pubmed ID: 21310823
Challenging diagnosis in a patient with clear lymphoid immunohistochemical features and myeloid morphology: mixed phenotype acute leukemia with erythrophagocytosis.
Leukemia research May, 2011 | Pubmed ID: 21334744
Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms.
British journal of haematology May, 2011 | Pubmed ID: 21385170
Chronic myeloid leukemia lysate-loaded dendritic cells induce T-cell responses towards leukemia progenitor cells.
Immunotherapy Apr, 2011 | Pubmed ID: 21463196
Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD.
Haematologica Sep, 2011 | Pubmed ID: 21606167
Class II-associated invariant chain peptide expression represents a novel parameter for flow cytometric detection of acute promyelocytic leukemia.
The American journal of pathology Nov, 2011 | Pubmed ID: 21907692
Azacitidine differentially affects CD4(pos) T-cell polarization in vitro and in vivo in high risk myelodysplastic syndromes.
Leukemia research Jul, 2012 | Pubmed ID: 22503132
Towards a joint definition of European hematology.
Haematologica May, 2012 | Pubmed ID: 22556351
Promiscuous binding of invariant chain-derived CLIP peptide to distinct HLA-I molecules revealed in leukemic cells.
PloS one , 2012 | Pubmed ID: 22563374
Tumor immune escape in acute myeloid leukemia: Class II-associated invariant chain peptide expression as result of deficient antigen presentation.
Oncoimmunology Mar, 2012 | Pubmed ID: 22720245
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group.
Leukemia & lymphoma Mar, 2013 | Pubmed ID: 22916713
Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK).
Blood Dec, 2012 | Pubmed ID: 23047822
A threshold of 10% for myeloperoxidase by flow cytometry is valid to classify acute leukemia of ambiguous and myeloid origin.
Cytometry. Part B, Clinical cytometry Mar, 2013 | Pubmed ID: 23325578
Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients.
Blood Mar, 2013 | Pubmed ID: 23325837
MicroRNA profiling can classify acute leukemias of ambiguous lineage as either acute myeloid leukemia or acute lymphoid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research Apr, 2013 | Pubmed ID: 23444217
Autologous Stem Cell Transplantation in elderly Acute Myeloid Leukemia.
Mediterranean journal of hematology and infectious diseases , 2013 | Pubmed ID: 23505606
MRD in AML: time for redefinition of CR?
Blood Mar, 2013 | Pubmed ID: 23520326
High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.
Annals of hematology Aug, 2013 | Pubmed ID: 23572137
Priming of PRAME- and WT1-specific CD8T cells in healthy donors but not in AML patients in complete remission: Implications for immunotherapy.
Oncoimmunology Apr, 2013 | Pubmed ID: 23734332
Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON).
European journal of cancer (Oxford, England : 1990) Oct, 2013 | Pubmed ID: 23876833
Targeting the acute myeloid leukemic stem cell compartment by enhancing tumor cell-based vaccines.
Immunotherapy Aug, 2013 | Pubmed ID: 23902555
Procedures for the expansion of CD14(+) precursors from acute myeloid leukemic cells to facilitate dendritic cell-based immunotherapy.
Immunotherapy Nov, 2013 | Pubmed ID: 24188673
Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells.
PloS one , 2013 | Pubmed ID: 24244383
Apoptotic blebs from leukemic cells as a preferred source of tumor-associated antigen for dendritic cell-based vaccines.
Cancer immunology, immunotherapy : CII Apr, 2014 | Pubmed ID: 24384837
Positioning of aminopeptidase inhibitors in next generation cancer therapy.
Amino acids Apr, 2014 | Pubmed ID: 24385243
Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
Cytometry. Part B, Clinical cytometry Jan, 2014 | Pubmed ID: 24431028
Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
Cytometry. Part B, Clinical cytometry May, 2014 | Pubmed ID: 24474614
Attenuation of microRNA-126 expression that drives CD34+38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication.
Cancer research Apr, 2014 | Pubmed ID: 24477595
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.
Haematologica Jul, 2014 | Pubmed ID: 24532039
High class II-associated invariant chain peptide expression on residual leukemic cells is associated with increased relapse risk in acute myeloid leukemia.
Leukemia research Jun, 2014 | Pubmed ID: 24731748
Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center.
Leukemia Feb, 2015 | Pubmed ID: 25113226
BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.
Cancer cell Sep, 2014 | Pubmed ID: 25132497
Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia.
PloS one , 2014 | Pubmed ID: 25244440
Genomic amplification of MYC as double minutes in a patient with APL-like leukemia.
Molecular cytogenetics , 2014 | Pubmed ID: 25392715
MRD in AML: it is time to change the definition of remission.
Best practice & research. Clinical haematology Sep-Dec, 2014 | Pubmed ID: 25455276
How I treat the older patient with acute myeloid leukemia.
Blood Jan, 2015 | Pubmed ID: 25515963
Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
Haematologica Mar, 2015 | Pubmed ID: 25527562
loading of skin dendritic cells with apoptotic bleb-derived antigens for the induction of tumor-directed immunity.
Oncoimmunology , 2014 | Pubmed ID: 25610730
Immunophenotyping for diagnosis and prognosis in MDS: ready for general application?
Best practice & research. Clinical haematology Mar, 2015 | Pubmed ID: 25659726
Regulatory T cells and progenitor B cells are independent prognostic predictors in lower risk myelodysplastic syndromes.
Haematologica Jun, 2015 | Pubmed ID: 25749828
Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG.
Haematologica Oct, 2015 | Pubmed ID: 26160876
Differential capacity of human interleukin-4 and interferon-α monocyte-derived dendritic cells for cross-presentation of free versus cell-associated antigen.
Cancer immunology, immunotherapy : CII Nov, 2015 | Pubmed ID: 26216454
A Human Cell Line Model for Interferon-α Driven Dendritic Cell Differentiation.
PloS one , 2015 | Pubmed ID: 26252775
Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR.
Oncotarget Feb, 2016 | Pubmed ID: 26496029
Application of flow cytometry for myelodysplastic syndromes: Pitfalls and technical considerations.
Cytometry. Part B, Clinical cytometry Jul, 2016 | Pubmed ID: 26517178
Chronic myeloid leukemia in the Netherlands: a population-based study on incidence, treatment, and survival in 3585 patients from 1989 to 2012.
European journal of haematology Aug, 2016 | Pubmed ID: 26519944
Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-trans retinoic acid.
Blood Jan, 2016 | Pubmed ID: 26582376
Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis.
The Lancet. Haematology Oct, 2015 | Pubmed ID: 26686044
Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias.
European journal of cancer (Oxford, England : 1990) Feb, 2016 | Pubmed ID: 26720403
Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia.
Haematologica Jan, 2016 | Pubmed ID: 26721801
Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.
European journal of cancer (Oxford, England : 1990) Mar, 2016 | Pubmed ID: 26798967
How to assess minimal residual disease in pediatric and adult acute myeloid leukemia?
Translational pediatrics Apr, 2013 | Pubmed ID: 26835296
Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research Aug, 2016 | Pubmed ID: 27006491
Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes.
Haematologica 02, 2017 | Pubmed ID: 27658438
MRD in AML: does it already guide therapy decision-making?
Hematology. American Society of Hematology. Education Program Dec, 2016 | Pubmed ID: 27913502
Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.
Blood Mar, 2017 | Pubmed ID: 28049642
Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial.
Genes, chromosomes & cancer Jul, 2017 | Pubmed ID: 28236351
Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.
Journal of cancer research and clinical oncology Aug, 2017 | Pubmed ID: 28364360
Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib.
Haematologica Aug, 2017 | Pubmed ID: 28522574
The interference of genetic associations in establishing the prognostic value of the immunophenotype in acute myeloid leukemia.
Cytometry. Part B, Clinical cytometry Jan, 2018 | Pubmed ID: 28646564
Specific Depletion of Leukemic Stem Cells: Can MicroRNAs Make the Difference?
Cancers Jun, 2017 | Pubmed ID: 28665351
Validation of and proposals for refinements of the WHO 2016 classification for myelodysplastic syndromes.
American journal of hematology Nov, 2017 | Pubmed ID: 28741674
Minimal/measurable residual disease in AML: consensus document from ELN MRD Working Party.
Blood Jan, 2018 | Pubmed ID: 29330221
Jacqueline Cloos*,1,2,
Jeffrey R. Harris*,3,
Jeroen J.W.M. Janssen1,
Angele Kelder1,
F. Huang3,
Gerrit Sijm1,
Maike Vonk1,
Alexander N. Snel1,
Jennifer R. Scheick1,
Willemijn J. Scholten1,
Jannemieke Carbaat-Ham1,
Dennis Veldhuizen1,
Diana Hanekamp1,
Yvonne J.M. Oussoren-Brockhoff1,
Gertjan J.L. Kaspers2,4,
Gerrit J. Schuurhuis1,
A. Kate Sasser3,
Gert Ossenkoppele1
JoVE 소개
Copyright © 2024 MyJoVE Corporation. 판권 소유